The Respiratory Microbiome in Chronic Hypersensitivity Pneumonitis Is Distinct from That of Idiopathic Pulmonary Fibrosis

Rachele Invernizzi1, Benjamin G. Wu2, Joseph Barnett1,3, Poonam Ghai1, Shaun Kingston1,3, Richard J. Hewitt1,3, Johanna Feary1,3, Yonghua Li2, Felix Chua3, Zhe Wu1,3, Athol U. Wells3, Peter M. George3, Elisabetta A. Renzoni3, Andrew G. Nicholson1,3, Alexandra Rice3, Anand Devaraj1,3, Leopoldo N. Segal2, Adam J. Byrne1, Toby M. Maher1*, Clare M. Lloyd1, and Philip L. Molyneaux1,3

1National Heart and Lung Institute, Imperial College London, London, United Kingdom; 2Division of Pulmonary and Critical Care Medicine, New York University, New York, New York; and 3Royal Brompton Hospital, London, United Kingdom

ORCID IDs: 0000-0002-6957-9626 (R.I.); 0000-0003-4294-0052 (R.J.H.).

Abstract

**Rationale:** Chronic hypersensitivity pneumonitis (CHP) is a condition that arises after repeated exposure and sensitization to inhaled antigens. The lung microbiome is increasingly implicated in respiratory disease, but, to date, no study has investigated the composition of microbial communities in the lower airways in CHP.

**Objectives:** To characterize and compare the airway microbiome in subjects with CHP, subjects with idiopathic pulmonary fibrosis (IPF), and control subjects.

**Methods:** We prospectively recruited individuals with a CHP diagnosis (n = 110), individuals with an IPF diagnosis (n = 45), and control subjects (n = 28). Subjects underwent BAL and bacterial DNA was isolated, quantified by quantitative PCR and the 16S ribosomal RNA gene was sequenced to characterize the bacterial communities in the lower airways.

**Measurements and Main Results:** Distinct differences in the microbial profiles were evident in the lower airways of subjects with CHP and IPF. At the phylum level, the prevailing microbiota of both subjects with IPF and subjects with CHP included *Firmicutes*, *Bacteroidetes*, *Proteobacteria*, and *Actinobacteria*. However, in IPF, *Firmicutes* dominated, whereas the percentage of reads assigned to *Proteobacteria* in the same group was significantly lower than the percentage found in subjects with CHP. At the genus level, the *Staphylococcus* burden was increased in CHP, and *Actinomyces* and *Veillonella* burdens were increased in IPF. The lower airway bacterial burden in subjects with CHP was higher than that in control subjects but lower than that of those with IPF. In contrast to IPF, there was no association between bacterial burden and survival in CHP.

**Conclusions:** The microbial profile of the lower airways in subjects with CHP is distinct from that of IPF, and, notably, the bacterial burden in individuals with CHP fails to predict survival.

**Keywords:** lung microbiota; 16S; fibrosis

(Received in original form February 28, 2020; accepted in final form July 21, 2020)

This article is open access and distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/).

*T.M.M. is Associate Editor of AJRCCM. His participation complies with American Thoracic Society requirements for recusal from review and decisions for authored works.

Supported by an Action for Pulmonary Fibrosis Mike Bray Fellowship (P.L.M.), a National Institute for Health Research Clinician Scientist Fellowship (CS-2013-13-017 to T.M.M.), a British Lung Foundation Chair in Respiratory Research grant (C17-3 to T.M.M.), a Wellcome Senior Fellowship in Basic Biomedical Science (107059/Z/15/Z to C.M.L.), a Wellcome Trust award (205949/Z/17/Z to A.J.B.), and an Asthma UK senior fellowship (AUK-SNF-2017-381 to A.J.B.).

Author Contributions: Conception and design: R.I. and P.L.M. Acquisition of data and pathologic data and recruitment: J.B., R.J.H., J.F., F.C., Z.W., A.U.W., E.A.R., A.G.N., A.R., A.D., and P.L.M. Analysis and interpretation: R.I., B.G.W., P.G., S.K., Y.L., L.N.S., A.J.B., T.M.M., C.M.L., and P.L.M. Drafting the manuscript: R.I. and P.L.M. Editing manuscript: R.I., B.G.W., F.C., A.G.N., A.R., L.N.S., A.J.B., T.M.M., C.M.L., and P.L.M. Final approval: all authors.

Correspondence and requests for reprints should be addressed to Philip L. Molyneaux, M.B. B.S., Ph.D., National Heart and Lung Institute, Imperial College London, London SW7 2AZ, UK. E-mail: p.molyneaux@imperial.ac.uk.

This article has a related editorial.

This article has an online supplement, which is accessible from the issue’s table of contents at www.atsjournals.org.
Hypersensitivity pneumonitis is an immune-mediated interstitial lung disease that develops in genetically susceptible individuals after repeated inhalation of organic antigens, including fungal, bacterial, animal, and insect proteins (1). It can be classified into acute and chronic forms, depending on the nature of the inciting antigen, the intensity and duration of exposure, host factors, and radiological findings (2). Chronic hypersensitivity pneumonitis (CHP) carries the most significant morbidity and mortality. It arises from protracted exposure to a triggering antigen, which initially elicits inflammation and ultimately evolves into irreversible and often progressive interstitial fibrosis (3, 4). As yet, there are no established international guidelines for the diagnosis of CHP, and it remains unclear why only some individuals exposed to recognized triggers develop the disease (5). This diagnostic uncertainty is further confounded in advanced disease because the clinical features of CHP and idiopathic pulmonary fibrosis (IPF) are often indistinguishable (6).

The existence of a microbiome in the healthy lung is generally accepted, and its potential role in respiratory pathology is increasingly appreciated (7–9). The advent of next-generation sequencing technologies has allowed direct and culture-independent sequence-based interrogation of microbial communities in both homeostatic and perturbed states (10, 11). Changes in the respiratory microbiome have been associated with the clinical, physiological, and therapeutic aspects of chronic lung diseases such as asthma, bronchiectasis, chronic obstructive pulmonary disease (COPD), and IPF (12–18). Studies of the respiratory microbiome in IPF have reported associations between changes in microbial communities and disease progression and mortality (16, 17, 19, 20). A higher bacterial burden has been reported during acute exacerbations of IPF (21, 22) and is consistently associated with an increased risk of mortality (16–18). Differences in bacterial community composition and diversity have also been correlated with disease outcomes, peripheral blood host-defense gene expression (19), and indices of alveolar inflammation (18). These observational studies support the hypothesis that the respiratory microbiome may be implicated in the pathogenesis of fibrotic lung disease (23, 24).

CHP and IPF are pathogenically and prognostically distinct disorders that are both characterized by irreversible fibrotic destruction of the lung parenchyma; we set out to test the hypothesis that observed alterations in the lung microbiome are disease specific and do not simply reflect the presence of fibrosis within the lung. In this study, we prospectively recruited individuals with CHP and IPF diagnoses as well as healthy control subjects to characterize the bacterial communities in the lower airways by 16s ribosomal (r)RNA gene sequencing. Despite the phenotypic overlap between CHP and IPF, we demonstrate that there are clear differences in patients with CHP in the microbial composition and bacterial burden of the lower airways and in survival, compared with healthy subjects and patients with IPF.

Methods

Study Design

Treatment-naïve subjects were prospectively recruited at the Royal Brompton Hospital (London) between May 2014 and May 2018. A diagnosis of IPF was made after multidisciplinary team discussion, according to the latest international guidelines (25). A consensus diagnosis of CHP was made using multidisciplinary team discussion with integration of clinical, radiological, BAL, and pathological data (5, 26). Pulmonary function testing was performed, clinical measurements were recorded, and subjects underwent fiberoptic bronchoscopy with BAL via the oropharyngeal route as part of standard care according to a standard operating procedure (27). BAL cell profiling was performed by assessing leukocyte differential counts. Computed tomographic data were scored as previously described (28). Approval for the study was obtained from the local research ethics committee (15/SC/0101 and 15-LO-1399), and written informed consent was obtained from all subjects. The IPF cohort was not used in any prior studies. See the online supplement for further details.

Bacterial DNA Isolation and 16s rRNA Amplicon Sequencing

Genomic DNA was extracted from BAL cell pellets as previously described, with minor modifications (29). Amplification of the V4 hypervariable region of the 16s rRNA gene was performed using the barcoded universal primer pair 515F/806R and sequenced using an Illumina MiSeq instrument (Illumina) to produce 150 base-paired reads. For full details, see the online supplement.
Bioinformatics Analysis
Reads were analyzed using the Quantitative Insights into Microbial Ecology 2 (version 2018.8) bioinformatics pipeline (30). Bioinformatics processing included demultiplexing, denoising, removal of chimeric and short reads, 97% identity binning of reads into amplicon sequence variants (ASV) using Divisive Amplicon Denoising Algorithm 2 (31), and taxonomic annotation using the Greengenes database (32). Absolute ASV sequence counts were normalized to obtain the relative abundances of the microbiota in each sample. After abundance filtering, a rarefied data set was generated and used for downstream analyses. For details on processing and quality control, see the online supplement.

16S RNA Gene Quantitative PCR
Triplicate 10-µl quantitative PCR (qPCR) reactions were set up containing 1 µl of bacterial DNA and 9 µl of Femto bacterial qPCR premix (Cambridge Bioscience). Each run contained a 10-fold dilution series of the Vibrio natriegens DSM 759 gene cloned into a plasmid of known size and a nontemplate control (28). For a description of cycling parameters, see the Methods section of the online supplement.

Statistical Analysis
All data analysis was performed in R (version 3.4.3; R Foundation for Statistical Computing) (33). Differences in BAL differential cell counts, bacterial burden, and taxonomic composition among subjects with CHP, subjects with IPF, and control subjects were statistically tested by using the Kruskal-Wallis test and the Dunn test for multiple comparisons, which was adjusted using the Bonferroni method. Univariate linear regressions between bacterial burden and BAL differential cell counts were performed and adjusted for age, sex, smoking status, and FVC using a multivariable linear regression model. Changes in microbial biodiversity and richness between subjects with CHP and subjects with IPF were evaluated using the Shannon and Chao1 diversity indexes and were tested using the Mann-Whitney test. The β-diversity of subjects with CHP and subjects with IPF was restricted to ASV that were present at >1% of the sample population, calculated using the Euclidean distance and visualized by principal component analysis (PCA), with the significance of differences in community composition being determined by permutational multivariate ANOVA adjusted for age, sex, smoking status, FVC (% predicted), and DLCO (% predicted). The linear discriminant analysis effect size was used to identify differentially abundant bacteria among the groups. To study CHP and IPF disease progression, a Kaplan-Meier curve was assessed using a multivariate Cox proportional-hazard model, adjusted for age, sex, smoking status, FVC (% predicted), and percentage of honeycombing. Survival time was defined as the time from diagnosis to death, loss to follow-up, or the end of the study period. In all analyses, a P value < 0.05 was considered statistically significant.

Data Availability
Sequences are available via the National Center for Biotechnology Information Sequence Read Archive (accession number PRJNA609242). Codes and metadata used for analysis are available at https://github.com/molyneaux-lab.

Results

Subjects, Sampling, and Sequencing
One hundred ten subjects with CHP, 45 subjects with IPF, and 28 control subjects were enrolled in the study and underwent bronchoscopy (Table 1). The demographics demonstrate a number of expected differences based on the known sex, smoking, and clinical profiles of both IPF and CHP (34). Subjects with IPF were predominantly male (82%), with a mean ± SD age of 62 ± 19 years and moderately severe restrictive lung disease (FVC, 75% predicted ± 19% predicted; Hb-adjusted DLCO 44% predicted ± 17% predicted). There were more female subjects in the CHP cohort, and although their mean age (66 ± 9 years) and Hb-adjusted DLCO (44% predicted ± 16% predicted) were matched, they had a more preserved FVC compared with the IPF cohort (85% predicted ± 23% predicted). The median follow-up in the CHP cohort was 919 days, and the median follow-up in the IPF cohort was 744 days (not significant). Although alveolar macrophages predominated in the BAL cells of all groups, a mixed alveolitis with predominant neutrophilia was observed in subjects with IPF (18% ± 6% neutrophils, 12% ± 5% lymphocytes), whereas subjects with CHP demonstrated an elevated lymphocyte count (32% ± 15% lymphocytes). Radiologically, the subjects with CHP had more ground-glass and low-density lobules and less honeycombing than subjects with IPF. In keeping with the literature, over half (52%) of the patients with CHP had no obvious exposure history. The majority of exposures in the CHP cohort were mold-related (20%), avian (15.45%) or feather down–related (5.45%). In contrast, only eight patients with IPF had an obvious exposure history (17.7%) (Table 1). All 183 samples yielded genomic DNA amplicons and underwent sequencing of the V4 region of the 16S rRNA gene. After demultiplexing, denoising, quality control, and abundance filtering, 8,406,014 sequences were retained, representing 495 unique ASV across 183 samples (35). This final curated data set was used for all subsequent analyses.

Bacterial Burden
The strongest and most robust microbial signature associated with fibrotic lung disease to date is that of the bacterial burden. We and others have already shown that IPF is characterized by an increased bacterial burden in BAL cells, which is associated with disease progression. We therefore initially set out to explore differences in the BAL bacterial burden among control subjects and subjects with CHP and IPF. On average, subjects with IPF had 1.54 × 105 copies of the 16S rRNA gene per milliliter of BAL fluid, which was higher than the average copy number in control subjects (8.57 × 103 copies/ml; P < 0.00001). Although subjects with CHP had a higher bacterial load (1.14 × 104) compared with healthy control subjects (P < 0.0001), they had a significantly lower burden compared with subjects with IPF (P < 0.00001) (Figure 1). No correlation was found between the bacterial load and the BAL differential cell counts (see Figure E1 in the online supplement). The negative control samples yielded a bacterial burden close to or below the lower limit of qPCR quantification (100 copies/ml of BAL fluid) (Figure E2).

Survival Analysis
The differences in survival between subjects with CHP and IPF were explored using a multivariate Cox regression analysis, and subjects with CHP were found to survive...
patients with IPF have an increased pulmonary bacterial load, the magnitude of which predicts the rate of progression of IPF and risk of mortality (16, 18). Collectively, these results suggest that the association between increased bacterial burden and survival is specific to IPF and is not seen in CHP.

**Description of BAL Microbiota Composition in Health and Disease**

Across all cohorts, the composition of the microbial communities was dominated by five most abundant phyla: *Firmicutes*, *Bacteroidetes*, *Proteobacteria*, *Actinobacteria*, and *Fusobacteria* (Figure 3A). At the phylum level, the microbiota of subjects with CHP was dominated by *Firmicutes* (38%), *Bacteroidetes* (24%), *Proteobacteria* (23%), and *Actinobacteria* (9%). Although the same phyla predominated in the subjects with IPF, there were a number of differences. In IPF, *Firmicutes* accounted for over 43% of the total reads, and the percentage of reads assigned to *Proteobacteria* was significantly lower compared with the percentage assigned in subjects with CHP (15% and 23%, respectively; *P* = 0.04). No significant differences were observed when comparing individuals with CHP with control subjects (Figure E3); in contrast, an increased abundance of *Firmicutes* (43%; *P* = 0.04) and *Actinobacteria* (11%; *P* = 0.04) was noted in subjects with IPF compared with control subjects (Figure E3). Comparison at the genus level identified that the microbial landscape of all groups was dominated by *Prevotella* (control subjects, 24%; subjects with CHP, 23%; subjects with IPF, 25%), *Veillonella* (control subjects, 13%; subjects with CHP, 14%; subjects with IPF, 18%), and *Streptococcus* (control subjects, 19%;
subjects with CHP (21%); subjects with IPF (18%) (Figure 3A). Of these genera, Veillonella (18%) was found to be most abundant in the BAL cells of subjects with IPF compared with the BAL cells of control subjects (13%; \( P = 0.02 \); Figure E4) and subjects with CHP (14%; \( P = 0.02 \)). Within the Actinobacteria phylum, there was a lower relative abundance of Actinomyces (4%) in subjects with CHP compared with individuals with IPF (6%; \( P = 0.001 \)) but not compared with control subjects (5%; \( P = 0.95 \); Figure E4). Staphylococcus was found to be increased in subjects with an IPF diagnosis (0.5%) compared with control subjects (0.1%; \( P = 0.03 \); Figure E4) but was most abundant in the CHP cohort (2%; \( P = 0.0005 \), compared with IPF cohort) (Figure 3A). Given the previous association between disease progression and an increased relative abundance of Streptococcus and Staphylococcus in IPF, we investigated whether these bacterial genera were associated with an increased risk of mortality in CHP and IPF. Using a univariate analysis, we found that both Streptococcus (hazard ratio, 2.07; 95% confidence interval, 0.83–5.16; \( P = 0.030 \)) and Staphylococcus (hazard ratio, 1.80; 95% confidence interval, 0.79–4.09; \( P = 0.033 \)) were significantly associated with increased mortality in IPF. However, consistent with the literature (17), the enrichment of these two bacteria was observed in less than half of the cohort; therefore, it remains unlikely that these organisms alone can explain the disease pathogenesis or progression. Repeating the same analysis in subjects with CHP, no associations between an increased abundance of either Streptococcus (hazard ratio, 1.04; 95% confidence interval, 0.34–3.19; \( P = 0.9 \)) or Staphylococcus (hazard ratio, 0.25; 95% confidence interval, 0.17–1.59; \( P = 0.3 \)) in the BAL cells of these individuals and disease progression were demonstrated (Figure E5). \( \alpha \)-Diversity metrics were used to characterize the distribution (evenness) and number (richness) of taxa expected within each sample. The microbial communities of subjects with IPF had a decreased evenness compared with those of the control subjects (\( P < 0.03 \)) but not compared with those of subjects with CHP. There were no differences in evenness when comparing control subjects with individuals with CHP. Similarly, there were no demonstrable changes when comparing microbial richness among the groups (Figure 3B).

Changes in the community composition (\( \beta \) diversity) between healthy control subjects and subjects with CHP and IPF were investigated using PCA and were tested by permutational multivariate ANOVA adjusted for age, sex, smoking status, FVC (% predicted) and DLCO (% predicted), which confirmed differences in the microbial profiles of the subjects on the basis of diagnosis (\( P = 0.001 \)) (Figure 3C). The PCA revealed that variation among the groups was mostly driven by changes in the Proteobacteria and Firmicutes phyla, with a tendency toward an enrichment of Firmicutes in the BAL from patients with IPF and of Proteobacteria in the BAL cells from patients with CHP. Community composition changes among the groups were further interrogated by looking for differentially abundant bacteria using the linear discriminant analysis effect size. Multiple taxonomic differences were found: the BAL fluid of subjects with IPF was enriched with bacteria belonging to the Firmicutes phylum, and the BAL fluid of the group with CHP was enriched with bacteria belonging to the Actinobacteria and Fusobacteria phyla. In contrast, those enriched in the healthy control group belonged to the Bacteroidetes phylum (Figure E6). Analyzing the CHP cohort on the basis of antigen positivity or negativity identified no differences between bacterial burden when comparing subjects with CHP with or without an exposure history to an antigen (Figure E7A). Similarly, no differences were observed in the microbial community composition (Figure E7B).
Discussion

There are clear differences in the composition of the lower airway respiratory microbiota in CHP compared with IPF. Although individuals with CHP have a higher bacterial load in BAL fluid compared with healthy control subjects, it remains significantly lower than that observed in subjects with IPF. In contrast to the mounting evidence for the role of the bacterial burden in IPF, no association was found between the bacterial burden and survival in subjects with CHP.

Over the past decade, studies have begun to unravel the causes and consequences of variation within the respiratory microbiota, improving our understanding of how it may be linked to the pathogenesis of lung diseases. Considerable advances in culture-independent technologies have not only enabled researchers to characterize niche-specific microbial ecosystems but have also enabled them to study the role of the microbiome in lung health and disease (10, 11). Although the spotlight in respiratory research has been on asthma, COPD, and IPF, CHP remains an understudied disease (12, 13, 15–18). Research into the lung microbiota in CHP is very limited; to date, no specific study has investigated the composition of microbial communities in the lower airways in CHP.

The baseline bacterial phyla that dominated the BAL fluid of control subjects and subjects with CHP and IPF in the present study were Firmicutes, Bacteroidetes, Proteobacteria, Actinobacteria, and Fusobacteria, which have previously been reported to be present in the airways of healthy subjects and patients with asthma, COPD, and IPF (10, 36). Marked differences were evident in the intergroup distribution of phyla. Specifically, an increased abundance of Firmicutes and Actinobacteria was noted in subjects with IPF compared with control subjects and subjects with CHP. In contrast, individuals with CHP had an increased proportion of Proteobacteria compared with individuals with IPF. This finding is consistent with the results of a recent study of subjects with IPF who had an increase in Firmicutes and a decrease in Proteobacteria; this reduction in microbial diversity was associated with disease activity in subjects with IPF (36). Furthermore, studies have shown that during respiratory disease, there is an increased prevalence of Firmicutes and Proteobacteria (12). This observation suggests that an altered state of the lung microbiome may be directly associated with the pathophysiology of fibrotic lung disease.

At the genus level, the microbial profile of all groups was characterized by Prevotella, Veillonella, and Streptococcus, bacteria known to prevail and/or dominate in the airways of healthy subjects and patients with respiratory disease (11). The phylum Firmicutes is associated with an increased risk of IPF progression when found at increased relative abundance in the lung (17). Specifically, within the Firmicutes phylum an increased abundance of Streptococcus and/or Staphylococcus species has been shown to be strongly correlated with reduced progression-free survival time in IPF (17). In the present study, Streptococcus was increased in subjects with IPF compared with healthy control subjects and was further increased in subjects with CHP compared with subjects with IPF. In addition, in agreement with previous findings, Veillonella was also found to be increased in subjects with IPF compared with control subjects (16) and subjects with CHP. We further delineated differences in microbial evenness and whole community composition between CHP and IPF. Collectively, these findings show that subjects with CHP have a distinct microbiome compared with patients with IPF and healthy control subjects, which suggest that alterations in the microbiome characterized by an increased abundance of bacteria belonging to the Firmicutes phylum may play a role in the pathogenesis of these interstitial lung diseases. However, we cannot as yet draw any causal conclusions about this altered respiratory microbiome in CHP ahead of functional and longitudinal studies to comprehensively examine pathogenic host–microbe interactions.

It has previously been shown that IPF is characterized by an increased bacterial burden in BAL fluid compared with control subjects and that the bacterial load at the time of diagnosis predicts rapidly progressive IPF and an increased risk of mortality (16, 17). Given the radiological overlap and similarities in clinical behavior between patients with CHP and patients with IPF, it was surprising to find such striking differences in the lower airway bacterial burden between these two groups of patients. Although the BAL bacterial load in subjects with CHP was higher compared with that in control subjects, it was still lower than that in patients with IPF. Comparable with authors of other studies, we validate the finding that a higher bacterial burden at the time of diagnosis predicts subsequent progression of IPF. This association was not evident in the group with CHP and may explain why immunosuppression has been shown to be harmful in IPF but remains widely used to treat CHP in the absence of similar observations (37). Regardless of bacterial burden, subjects with CHP survived longer than individuals with IPF, a result that mirrors the findings of Vasakova and colleagues (38).

Closely associated with the alterations in the microbial composition is the change in the host immune status of patients with fibrotic lung disease. Specifically, lymphocytes, which are markedly increased in the airways of patients with CHP, play a key role in the inflammatory process underpinning the pathogenesis of the condition (39). An increased proportion of BAL lymphocytes was also present in the subjects with CHP in the present study. However, in agreement with what has been previously shown in IPF (16), no associations were found between BAL differential leukocyte counts and the bacterial burden in these subjects. It is increasingly recognized that a reciprocal communication likely exists between the microbiome and the pulmonary immune system, which may be critical for promoting pathology in a number of respiratory conditions (40). Future elucidation of microbial composition as well as the immune-cell subsets involved will improve our understanding of the cross-talk between microbiome and host.

There are a number of limitations to our work. Procedural and sequencing contamination presents a critical problem when evaluating samples with low microbial biomass, such as samples from the lungs (41). To minimize the risk of contamination, low-biomass protocols for DNA extraction were used, and negative bronchoscopy control subjects and reagent control subjects were sequenced alongside the BAL samples. The inclusion of the negative control samples, which yielded a bacterial burden close to or below the lower limit of qPCR quantification (100 copies/ml of BAL fluid) and had a taxonomic profile
Figure 3. Taxonomic composition of bacteria in BAL of healthy control subjects and subjects with chronic hypersensitivity pneumonitis (CHP) and idiopathic pulmonary fibrosis (IPF). (A) Relative abundance of bacteria at the phylum (Bacteroidetes, Firmicutes, Proteobacteria, Actinobacteria, and Fusobacteria) and genus (Prevotella, Streptococcus, Veillonella, Neisseria, Haemophilus, Actinomyces, Rothia, Fusobacterium, Actinobacillus, and Staphylococcus) level. Statistical significance was tested by using the Kruskal-Wallis test with the Dunn multiple-comparison test adjusted with the Bonferroni method. Statistical differences between CHP and IPF are indicated by black asterisks, and those between control subjects and IPF are indicated by red asterisks (*P < 0.05, **P < 0.01, and ***P < 0.001). Data are presented as the mean ± SD. (B) Shannon and Chao1 α-diversity measures comparing healthy control subjects and individuals with CHP and IPF diagnoses. Statistical significance was tested by using the Kruskal-Wallis test with the Dunn multiple-comparison test adjusted with the Bonferroni method. Data are presented as the median and interquartile range. (C) PC analysis on Euclidean distance comparing healthy control subjects, subjects with CHP, and subjects with IPF (permutational multivariate ANOVA [PERMANOVA], P < 0.001). PERMANOVA was adjusted for age, sex, smoking status, FVC (% predicted), and DlCO (% predicted). PC = principal component.
distinct from that of the BAL specimens, robustly indicates that the sequencing protocol used resulted in no apparent contamination. Furthermore, samples from case patients and control subjects were always processed in a blinded, randomized fashion to uphold identical storage and processing conditions across all samples. Another significant limitation is that 16S rRNA gene sequencing provides a snapshot of the microbial community at a particular moment in time, and it is therefore challenging to draw conclusions regarding whether the altered microbial community is a cause or a consequence of the disease (42). Finally, this exploratory study was based on feasibility of recruitment and sampling, and some of the most severe cases of both CHP and IPF may have not been included, as only subjects able to safely undergo bronchoscopy were enrolled. Therefore, functional and longitudinal studies examining host–microbe interactions are needed to validate these findings.

In conclusion, in this prospective observational cohort study, we provide the first evidence of the composition of the microbial communities in the lower airways in CHP. The microbial profile of subjects with CHP is distinct from that of subjects with IPF. Compared with subjects with IPF, these individuals have a decreased bacterial burden, which does not predict survival. Future work should aim at understanding whether the total bacterial load and relative abundances of the altered microbial genera may be acting synergistically to advance the fibrotic process.

Author disclosures are available with the text of this article at www.atsjournals.org.

Acknowledgment: The authors would like to thank the Clinical Data Warehouse team at Royal Brompton and Harefield National Health Service Foundation Trust.

References
1. Salisbury ML, Myers JL, Belloli EA, Kazerooni EA, Martinez FJ, Flaherty KR. Diagnosis and treatment of fibrotic hypersensitivity pneumonia: where we stand and where we need to go. Am J Respir Crit Care Med 2017;196:690–699.
2. Selman M, Pardo A, King TE Jr. Hypersensitivity pneumonitis: insights in diagnosis and pathobiology. Am J Respir Crit Care Med 2012;186: 314–324.
3. Campbell JM. Acute symptoms following work with hay. Br Med J 1932; 2:1143–1144.
4. Morell F, Villar A, Montero MA, Muñoz X, Colby TV, Pipvath S, et al. Chronic hypersensitivity pneumonitis in patients diagnosed with idiopathic pulmonary fibrosis: a prospective case-cohort study. Lancet Respir Med 2013;1:685–694.
5. Morisset J, Johansson KA, Jones KD, Wolters PJ, Collard HR, Walsh SLF, et al.; HP Delphi Collaborators. Identification of diagnostic criteria for chronic hypersensitivity pneumonitis: an international modified Delphi survey. Am J Respir Crit Care Med 2018;197: 1036–1044.
6. Silva CI, Müller NL, Lynch DA, Curran-Elverett D, Brown KK, Lee KS, et al. Chronic hypersensitivity pneumonitis: differentiation from idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia by using thin-section CT. Radiology 2008;246:288–297.
7. Dickson RP, Erb-Downward JR, Martinez FJ, Hunninghake GB. The microbiome and the respiratory tract. Annu Rev Physiol 2016;78:481–504.
8. Charison ES, Bittinger K, Haas AR, Fitzgerald AS, Frank I, Yadav A, et al. Topographical continuity of bacterial populations in the healthy human respiratory tract. Am J Respir Crit Care Med 2011;184:957–963.
9. Invernizzi R, Lloyd CM, Molyneaux PL. Respiratory microbiome and epithelial interactions shape immunity in the lungs. Immunology 2020; 160:171–182.
10. Moffatt MF, Cookson WO. The lung microbiome in health and disease. Clin Med (Lond) 2017;17:525–529.
11. Dickson RP, Erb-Downward JR, Hunninghake GB. The role of the bacterial microbiome in lung disease. Expert Rev Respir Med 2013;7:245–257.
12. Hilty M, Burke C, Pedro H, Cardenas P, Bush A, Bossley C, et al. Disordered microbial communities in asthmatic airways. PLoS One 2010;5:e8578.
13. Stokholm J, Blaser MJ, Thorsen J, Rasmussen MA, Waage J, Vinding RK, et al. Maturation of the gut microbiome and risk of asthma in childhood. Nat Commun 2018;9:141.
14. Cox MJ, Turek EM, Hennessy C, Mirza GK, James PL, Coleman M, et al. Longitudinal assessment of sputum microbiome by sequencing of the 16S rRNA gene in non-cystic fibrosis bronchiectasis patients. PLoS One 2017;12:e0170622.
15. Molyneaux PL, Mallia P, Cox MJ, Footitt J, Willis-Owen SA, Homola D, et al. Outgrowth of the bacterial airway microbiome after rhinovirus exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013;188:1224–1231.
16. Molyneaux PL, Cox MJ, Willis-Owen SA, Mallia P, Russell KE, Russell AM, et al. The role of bacteria in the pathogenesis and progression of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2014;190: 906–913.
17. Han MK, Zhou Y, Murray S, Tayob N, Noth I, Lama VN, et al.; COMET Investigators. Lung microbiome and disease progression in idiopathic pulmonary fibrosis: an analysis of the COMET study. Lancet Respir Med 2014;2:548–556.
18. O’Dwyer DN, Ashley SL, Gurczynski SJ, Xia M, Wilke C, Falkowski NR, et al. Lung microbiota contribute to pulmonary inflammation and disease progression in pulmonary fibrosis. Am J Respir Crit Care Med 2019;199:1127–1138.
19. Molyneaux PL, Willis-Owen SAG, Cox MJ, James P, Cowman S, Loebinger M, et al. Host-microbial interactions in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2017;195: 1640–1650.
20. Huang Y, Ma SF, Espindola MS, Vij R, Oldham JM, Hunninghake GB, et al.; COMET-IPF Investigators. Microbes are associated with host innate immune response in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2017;196:208–219.
21. Molyneaux PL, Cox MJ, Wells AU, Kim HC, Ji W, Cookson WO, et al. Changes in the respiratory microbiome during acute exacerbations of idiopathic pulmonary fibrosis. Respir Res 2017; 18:29.
22. Invernizzi R, Molyneaux PL. The contribution of infection and the respiratory microbiome in acute exacerbations of idiopathic pulmonary fibrosis. Eur Respir Rev 2019;28:190045.
23. Cho I, Blaser MJ. The human microbiome: at the interface of health and disease. Nat Rev Med 2012;13:260–270.
24. Renz H, Autenrieth IB, Brandtzaeg P, Cookson WO, Holgate S, von Mutius E, et al. Gene-environment interaction in chronic disease: a European Science Foundation Forward Look. J Allergy Clin Immunol 2011;128:S27–S49.
25. Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, et al.; American Thoracic Society; European Respiratory Society; Japanese Respiratory Society; Latin American Thoracic Society. Diagnosis of idiopathic pulmonary fibrosis: an official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med 2018; 198:e44–e68.
26. Ryerson CJ, Corte TJ, Lee JS, Richeldi L, Walsh SLF, Myers JL, et al. A standardized diagnostic ontology for fibrotic interstitial lung disease: an International Working Group Perspective. Am J Respir Crit Care Med 2017;196:1249–1254.
27. Meyer KC, Raghu G, Baughman RP, Brown KK, Costabel U, du Bois RM, et al.; American Thoracic Society Committee on BAL in Interstitial Lung Disease. An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. Am J Respir Crit Care Med 2012;185:1004–1014.

28. Invernizzi R, Barnett J, Rawal B, Nair A, Ghai P, Kingston S, et al. Bacterial burden in the lower airways predicts disease progression in idiopathic pulmonary fibrosis and is independent of radiological disease extent. Eur Respir J 2020;55:1901519.

29. DeAngelis KM, Brodie EL, DeSantis TZ, Andersen GL, Lindow SE, Firestone MK. Selective progressive response of soil microbial community to wild oat roots. ISME J 2009;3:168–178.

30. Caporaso JG, Kuczynski J, Stombaugh J, Bittinger K, Bushman FD, Costello EK, et al. QIIME allows analysis of high-throughput community sequencing data. Nat Methods 2010;7:335–336.

31. Callahan BJ, McMurdie PJ, Rosen MJ, Han AW, Johnson AJ, Holmes SP. DADA2: high-resolution sample inference from Illumina amplicon data. Nat Methods 2016;13:581–583.

32. McDonald D, Price MN, Goodrich J, Nawrocki EP, DeSantis TZ, Probst A, et al. An improved Greengenes taxonomy with explicit ranks for ecological and evolutionary analyses of bacteria and archaea. ISME J 2012;6:610–618.

33. R Core Team. A language and environment for statistical computing. Version 3.4.3. Vienna, Austria: R Foundation for Statistical Computing; 2013.

34. Spagnolo P, Rossi G, Cavazza A, Bonifazi M, Paladini I, Bonella F, et al. Hypersensitivity pneumonitis: a comprehensive review. J Investig Allergol Clin Immunol 2015;25:237–250; quiz following 250.

35. Callahan BJ, Sankaran K, Fukuyama JA, McMurdie PJ, Holmes SP. Bioconductor workflow for microbiome data analysis: from raw reads to community analyses. F1000 Res 2016;5:1492.

36. Takahashi Y, Saito A, Chiba H, Kuronuma K, Ikeda K, Kobayashi T, et al. Impaired diversity of the lung microbiome predicts progression of idiopathic pulmonary fibrosis. Respir Res 2018;19:34.

37. Raghu G, Anstrom KJ, King TE Jr, Lasky JA, Martinez FJ; Idiopathic Pulmonary Fibrosis Clinical Research Network. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med 2012;366:1968–1977.

38. Vasakova M, Morell F, Walsh S, Leslie K, Raghu G. Hypersensitivity pneumonitis: perspectives in diagnosis and management. Am J Respir Crit Care Med 2017;196:680–689.

39. Pereira CA, Gimenez A, Kuranishi L, Storrer K. Chronic hypersensitivity pneumonitis. J Asthma Allergy 2016;9:171–181.

40. O’Dwyer DN, Dickson RP, Moore BB. The lung microbiome, immunity, and the pathogenesis of chronic lung disease. J Immunol 2016;196:4839–4847.

41. Saltar SJ, Cox MJ, Turek EM, Calus ST, Cookson WO, Moffatt MF, et al. Reagent and laboratory contamination can critically impact sequence-based microbiome analyses. BMC Biol 2014;12:87.

42. Hewitt RJ, Molyneaux PL. The respiratory microbiome in idiopathic pulmonary fibrosis. Ann Transl Med 2017;5:250.